Medindia

X

Hemispherx Biopharma and Max Neeman International Team Initiate Influenza Research Programs

Thursday, April 1, 2010 General News J E 4
Advertisement
. . . Clinical Sites Targeted to Enroll Subjects Beginning in Upcoming Monsoon Season

Company/Investor Contact:

Company/Investor Contact:

Dianne Will

Donald Swankie

Hemispherx Biopharma, Inc.

Max Neeman International

518.398.6222

919.424.3345

ir@hemispherx.net

donald.swankie@neeman-medical.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Blood Donors Contribute to World Health
S
New Report Addresses Potential Benefits and Shortc...